%20(2).png){kind=logo}
Ostro CEO Chase Feiger explains how regulatory compliance can serve as a strategic enabler, fostering trust and accelerating AI innovation in pharmaceutical development.
Big Pharma is adopting marketing tactics from pro athletes—such as personal branding, storytelling, and influencer-style engagement—to build trust and connect more authentically with patients.
Trump’s proposed megabill includes provisions that could boost the biotech industry, particularly by streamlining FDA approvals and expanding support for domestic biomanufacturing.
GLP-1 drugs like Ozempic are reshaping consumer behavior beyond food by disrupting industries such as retail, casinos, airlines, and fitness, prompting brands to rethink engagement strategies.
Donald Trump's 2024 campaign and potential second term could reshape U.S. healthcare policy, including deregulation, cost transparency, and the rollback of Biden-era initiatives.
Chase Feiger outlines four essential strategies—ensuring regulatory compliance, fostering explainable AI, aligning with real-world life‑sciences use cases, and building strong cross-functional teams—to successfully implement AI in life-sciences organizations.
Senators are pushing to regulate or limit direct-to-consumer pharmaceutical advertising, raising concerns in the industry that such actions could threaten its $2 billion R&D investment model.
.svg)